Airway myeloperoxidase (MPO) is associated with increased risk of exacerbations in COPD
S. Rosengren (Gothenburg, Sweden), S. Tångefjord (Gothenburg, Sweden), G. De Palo (Gothenburg, Sweden), J. Horndahl (Gothenburg, Sweden), M. Ingelsten (Gothenburg, Sweden), A. Gilmour (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), K. Ostridge (Gothenburg, Sweden), J. Chalmers (Dundee, United Kingdom)
Source: International Congress 2022 – It is all about communication: novel interactions between lung structural cells and the immune system
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Rosengren (Gothenburg, Sweden), S. Tångefjord (Gothenburg, Sweden), G. De Palo (Gothenburg, Sweden), J. Horndahl (Gothenburg, Sweden), M. Ingelsten (Gothenburg, Sweden), A. Gilmour (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), K. Ostridge (Gothenburg, Sweden), J. Chalmers (Dundee, United Kingdom). Airway myeloperoxidase (MPO) is associated with increased risk of exacerbations in COPD. 2939
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|